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Abstract
Background: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in Western countries.
Developing more effective NSCLC therapeutics will require the elucidation of the genetic and biochemical bases for this
disease. Bronchioalveolar stem cells (BASCs) are a putative cancer stem cell population in mouse models of oncogenic K-ras-
induced lung adenocarcinoma, an histologic subtype of NSCLC. The signals activated by oncogenic K-ras that mediate BASC
expansion have not been fully defined.
Methodology/Principal Findings: We used genetic and pharmacologic approaches to modulate the activity of
phosphatidylinositol 3-kinase (PI3K), a key mediator of oncogenic K-ras, in two genetic mouse models of lung
adenocarcinoma. Oncogenic K-ras-induced BASC accumulation and tumor growth were blocked by treatment with a small
molecule PI3K inhibitor and enhanced by inactivation of phosphatase and tensin homologue deleted from chromosome 10,a
negative regulator of PI3K.
Conclusions/Significance: We conclude that PI3K is a critical regulator of BASC expansion, supporting treatment strategies
to target PI3K in NSCLC patients.
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Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of
cancer-related death in Western countries and its incidence is
rising in Asia. Once it has metastasized, there are no curative
therapies for NSCLC. A better understanding of the pathogenesis
and risk factors for this disease will contribute not only to
improvements in early detection and prevention but also to the
development of more effective therapies for it.
Approximately 10% of NSCLC specimens carry activating
mutations in K-ras [1]. The histologic subtype of NSCLC that most
frequently has K-ras mutations is adenocarcinoma; 30% of
adenocarcinomas have these mutations. K-ras mutations have also
been identified in atypical adenomatous hyperplasia (AAH)
lesions, which are thought to precede the development of lung
adenocarcinoma [2]. A growing body of evidence indicates that K-
ras mutations are important in the initiation of lung adenocarci-
noma development. Mouse models have been developed that
express mutant K-ras conditionally, somatically, or inducibly [3–7].
These mice develop AAH lesions rapidly and with high
penetrance, and a subset of these lesions progress to adenocarci-
nomas.
A candidate lung cancer progenitor cell (bronchioalveolar stem
cell or BASC) has been identified in murine models of K-ras-
induced lung cancer. BASCs have a specific pattern of stem cell
marker expression (Sca-1
pos CD34
pos CD45
neg Pecam
neg), are
located at the terminal bronchi, and have the capacity to self-
renew and undergo multi-linage differentiation [8]. These cells
may be the same as the variant Clara (or Clara
V) cells, which are
located adjacent to clusters of neuroendocrine bodies in bronchi
and bronchioles. Similar to BASCs, Clara
V cells are capable of
restoring the Clara cell population after naphthalene injury [9].
After intra-nasal installation of adenoviral Cre into Kras
LSL mice,
which develop lung adenocarcinoma due to activation of a
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prior to the development of histologic abnormalities [8]. The
BASCs in these mice contain K-ras mutations identical to those
found in tumors [8]. On the basis of this evidence, BASCs are
postulated to be progenitors of lung adenocarcinoma in mice. The
biochemical signals that initiate the expansion of this cellular
population have not been fully elucidated. This deficiency is
important given that the elucidation of these signals might lead to
better treatment for NSCLC patients.
Premalignant lesions typically undergo a transient expansion
followed by programmed senescence, and only a minority of early
lesions progresses to a fully transformed state. In the case of Ras-
dependent cancer mouse models, the programmed senescence of
premalignant lesions is activated by mitogen-activated protein
kinase kinase/extracellular signal-regulated kinase signaling, which
inhibits Ras through feed-back pathways involving increased
expression of SPROUTY proteins, Ras GTPase activating
proteins, and mitogen-activated protein kinase phosphatase-3
[10]. The senescence program in premalignant lesions can be
blocked by phosphatidylinositol 3-kinase (PI3K) activation [10],
indicating that PI3K is a crucial determinant of the malignant
progression of these lesions. In fact, PI3K signaling is constitutively
activated in NSCLC cells through inactivating somatic mutations
in, or epigenetic silencing of, phosphatase and tensin homologue deleted
from chromosome 10 (Pten), a lipid phosphatase that negatively
regulates the PI3K signaling cascade [11–15].
In this study, we evaluated the importance of PI3K in regulating
the expansion of BASCs in two genetic mouse models of oncogenic
K-ras-induced lung cancer. The oncogenic K-ras alleles in these
models are activated somatically in one (Kras
LA1) and condition-
ally in the other (Kras
LSL) (5, 7). We found increased numbers of
BASCs in these mice relative to those of wild-type littermates.
BASC expansion and malignant progression in the lung were
attenuated by pharmacologic inhibition of PI3K and enhanced by
genetic inactivation of Pten. We speculate on the basis of these
findings that pharmacologic strategies to inhibit PI3K will be
useful in the prevention and treatment of NSCLC.
Results
PX-866 inhibits lung tumorigenesis in Kras
LA1 mice
We postulated that PI3K is required for malignant progression
in lung cancer and tested this hypothesis by using Kras
LA1 mice as
a model of lung tumorigenesis. Several weeks after birth, Kras
LA1
mice exhibit multifocal AAH lesions that, by 2–3 months of age,
coalesce into solid or papillary adenomas, which enlarge and
undergo histologic transformation into adenocarcinomas by 6–
8 months [7]. We first evaluated the expression of PI3K (p110a
and b isoforms) in lung tissues at different stages of tumorigenesis
(AAH, adenoma, or adenocarcinoma). These PI3K isoforms were
detected and their abundance increased with malignant progres-
sion (AAH lesions versus adenocarcinomas: P=0.006 for p110a;
P,0.001 for p110b) (Figure 1A).
Based on its increased abundance in fully transformed cells, we
next sought to determine whether PI3K was required for tumor
growth. Treatment of K-ras
LA1 mice with PX-866, a PI3K
inhibitor [16], decreased lung lesion volume and multiplicity
(Figure 1B). This was accompanied by reductions in PI3K activity
as shown by western blotting of whole-lung lysates for phosphor-
ylated AKT and glycogen synthase kinase-3 (Figure 1C). Tumor
cells underwent a reduction in proliferation caused by PX-866
based on intra-lesional phosphorylated histone H3 (Figure 1D) but
exhibited no biochemical evidence of apoptosis as shown by
western blotting for cleaved caspase-3 and Poly (ADP-ribose)
polymerase (data not shown). Thus, treatment with a PI3K
antagonist profoundly inhibited the growth of these early lesions.
BASCs are highly sensitive to PX-866 in vivo and in vitro
We next determined whether the anti-tumor effect of PX-866 in
Kras
LA1 mice was partly due to inhibition of BASC expansion. At
the terminal bronchi, a subset of epithelial cells expressed both
clara cell specific protein (CCSP) and surfactant protein-C (SPC)
(Figure 2), which is a hallmark of BASCs [8]. Quantification of
dual-positive cells in wild-type mice (with 83 bronchi) and K-
ras
LA1 mice (with 66 bronchi) revealed that no wild-type mice had
more than 3 BASCs per terminal bronchus, whereas a subset of
terminal bronchi in K-ras
LA1 mice had 4 to 7 (P=0.042, wild-type
versus Kras
LA1) (Figure 2). Thus, a subset of terminal bronchi in
Kras
LA1 mice had BASC expansion. Furthermore, triple immu-
nofluorescence studies revealed that BASCs expressed p110a and
had detectable phosphorylation of AKT (Figure 3), a downstream
mediator of PI3K, providing evidence of PI3K activation in these
cells. Using tissue sections from the Kras
LA1 mice treated with PX-
866 (with 88 terminal bronchi) or vehicle (with 81 terminal
bronchi), we determined the number of BASCs per terminal
bronchus in the treatment groups. The vehicle-treated mice had a
subset of terminal bronchi with 4 to 7 BASCs per terminal
bronchus, whereas none of the PX-866-treated mice had more
than three BASCs per terminal bronchus (P=0.025, vehicle versus
PX-866-treated) (Figure 4).
To determine whether PX-866 had direct effects on Kras
LA1–
derived BASCs, we used primary BASC cultures, which were
isolated from the lungs of Kras
LA1 mice by sorting for cells that
were Sca-1
pos, CD34
pos, CD45
neg, and CD31
neg. These sorted
cells co-expressed CCSP and SPC (Figure 5A), formed colonies
when plated on feeder cultures (Figure 5B), and exhibited multi-
potential differentiation capacity when plated in matrigel
(Figure 5C), which are hallmarks of BASCs [8]. PX-866 treatment
led to a prominent decrease in BASC colony forming activity
(Figure 5D), indicating that PX-866 had a direct effect on BASCs.
Pten deficiency enhances oncogenic K-ras-induced BASC
accumulation
As another approach to evaluating the role of PI3K in BASC
expansion, we inactivated Pten, a negative regulator of PI3K, in
CCSP-expressing cells. Pten was genetically inactivated by using
Pten
flox/+ mice, which have a Pten allele that contains LoxP sites
surrounding the PTEN phosphatase domain encoded by exon 5
[17]. Pten was recombined specifically in the lung by interbreeding
these mice with CCSP
Cre/+ mice, which express Cre under the
control of the CCSP gene [18]. In addition, we evaluated whether
Pten inactivation cooperated with oncogenic K-ras to promote
BASC expansion. Pten-deficient mice were interbred with K-ras
LSL
mice, in which the expression of oncogenic K-ras
G12D is controlled
by a removable transcription termination STOP element [5].
Using this approach, mice were generated with bronchi that are
Pten-deficient (Pten
D5/D5; CCSP
Cre/+), express oncogenic K-ras
(Kras
Lox/+; CCSP
Cre/+), have Pten deficiency and oncogenic K-ras
expression (Pten
D5/D5; Kras
Lox/+; CCSP
Cre/+), or have neither
(Pten
flox/flox; CCSP
+/+). Mice were sacrificed at 4 weeks or
12 weeks, and their lung tissues were subjected to immunofluo-
rescence studies to quantify BASCs.
As expected, triple immunofluorescence staining (CCSP/SPC/
PTEN) revealed loss of PTEN expression in BASCs from mice that
were both Pten-deficient and K-ras-transformed (Pten
D5/D5;K r a s
Lox/
+;C C S P
Cre/+) but not in mice that were only K-ras-transformed
(Kras
Lox/+;C C S P
Cre/+) (Figure 6). Quantification of BASCs per
terminal bronchus at 4 weeks revealed that Pten-deficiency alone
PI3K in BASC Expansion
PLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2220(Pten
D5/D5;CCSP
Cre/+) wasnotsufficienttochangeBASCnumbers
relative to that of control mice (Pten
flox/flox;C C S P
+/+) (Figure 7).
However, comparison of BASC numbers in Pten
D5/D5; Kras
Lox/
+; CCSP
Cre/+ mice to that of Kras
Lox/+; CCSP
Cre/+ mice
demonstrated that Pten deficiency strikingly enhanced BASC
expansion by oncogenic K-ras (P=0.006, Pten
D5/D5; Kras
Lox/+;
CCSP
Cre/+ versus Kras
Lox/+; CCSP
Cre/+) (Figure 7). In addition
to these findings at the terminal bronchi, clusters of CCSP
pos
SPC
pos cells were observed in the bronchioles and small bronchi
of Pten
D5/D5; Kras
Lox/+; CCSP
Cre/+ mice; these cell clusters
were evident as early as 4 weeks of age and were not present in
the bronchi or bronchioles of Kras
Lox/+; CCSP
Cre/+ mice
(Figure 8). We conclude that Pten inactivation cooperated with
oncogenic K-ras to enhance BASC accumulation.
Discussion
Here we report that PI3K was required for BASC expansion
initiated by oncogenic K-ras and, when constitutively activated by
Pten inactivation, PI3K cooperated with oncogenic K-ras in this
process. This conclusion was based on findings from experiments
that incorporated pharmacologic and genetic approaches to
target PI3K in two different genetic mouse models and an in vitro
model. We have previously reported that Pten inactivation
cooperates with oncogenic K-ras to accelerate lung tumorigenesis,
causing lung tumors that are more histologically advanced and
more rapidly obstruct bronchial lumina and replace alveolar
spaces than those of mice with oncogenic K-ras alone [18].
Together, these findings raise the possibility that PI3K promoted
lung tumorigenesis through its effects on BASCs. However,
conclusive evidence in this regard will require proof that
adenocarcinomas arise from BASCs. Transplantation studies to
determine whether BASC injections are sufficient to recapitulate
lung adenocarcinoma development in mice have thus far not been
reported. A stem cell population has been identified in the lungs of
mice and in tumors from NSCLC patients that expresses CD133,
exhibits stem cell characteristics in vitro (forms spheres and can be
induced to undergo terminal differentiation), and is tumorigenic in
nude mice [19]. Although certain features of that stem cell
population are similar to those of BASCs (i.e. response to
Figure 1. PI3K promotes tumorigenesis in Kras
LA1 mice. (A) PI3K expression increases with malignant progression. Representative
immunohistochemical staining of lesions in the tissue microarray and their quantification in adjacent bar graphs. Calibration bar in lower right panel
represents 100 mm. Scores of mixed (solid/papillary) adenomas are included in bar graphs but not in PI3K staining images. (B) PI3K is required for
tumor growth. Mean changes in tumor multiplicity and volume determined by micro-computed tomography performed before and after treatment.
(* P,0.05 compared to vehicle). (C) PX-866 inhibits PI3K in lung tissues. Western blotting of Ser473-phosphorylated AKT (P-AKT) and Ser21/9-
phosphorylated GSK3 (P-GSK3a/b) in whole lung lysates from mice (n=7 in each treatment cohort). Positions of molecular weight markers are
indicated on the left. (D) PX-866 decreases tumor cell proliferation. Representative immunohistochemical staining of Ser28-phosphorylated histone
H3 (P-H3) in adenomas in the tissue microarray (x 20 magnification, areas with positive cells encircled) and quantification of staining in 16 lesions
from vehicle-treated mice and 4 lesions from PX-866-treated mice (bar graph, * P,0.05 compared to vehicle). Inset illustrates encircled cells at 640
magnification. Calibration bars represent 200 mm.
doi:10.1371/journal.pone.0002220.g001
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elucidated.
When initiated during embryogenesis, conditional Pten inacti-
vation in the lung leads to hypoxia and perinatal death, indicating
that Pten expression is required for normal lung development [20].
In this study, Cre expression in CCSP
Cre mice began at postnatal
day 4, allowing us to evaluate Pten’s role in maintaining lung
function after birth. Although we can not exclude the possibility
that subtle changes in lung function occurred, the Pten-deficient
mice in this study had no obvious alterations in their lung
structure and exhibited no morbidity at up to 12 months
of age, suggesting that, after birth, lung tissues can function
normally without Pten. This apparent resilience of lung tissues
to Pten deficiency stands in contrast to adult hematopoietic
stem cells, which are depleted within 40 days after inactivation
of Pten [21], indicating that the self-renewal capabilities of
hematopoietic stem cells can not be maintained in the absence
of PTEN’s negative growth regulatory signals. Although the
reasons for this difference are not clear, it may be related in
part to the relative infrequency with which lung stem cells
normally divide [9].
PI3K has been reported to play an important role in
tumorigenesis initiated by oncogenic K-ras. Kras
LA2 mice that
have a knock-in PIK3CA mutation that blocks the interaction of
PI3K with K-ras develop far fewer lung tumors than do Kras
LA2
mice with wild-type PIK3CA [22], indicating a key role for PI3K as
a downstream mediator of K-ras. Corroborating this point, we
found that PX-866 treatment inhibited lung tumor growth in
Kras
LA1 mice. However, based on other findings reported here,
the importance of PI3K in K-ras-induced lung tumorigenesis may
not be restricted to its role as a downstream mediator of K-ras.
First, PI3K expression increased as Kras
LA1 lung tissues
underwent malignant progression from AAH to adenocarcinoma,
suggesting that PI3K was activated in these histologically
advanced lesions in part through K-ras-independent mechanisms.
Second, findings reported here and elsewhere [18] indicate that
Pten inactivation enhanced oncogenic K-ras–induced lung tumor-
igenesis in mice. Extrapolating from these findings, somatic
mutations in NSCLC cells involving genes that regulate PI3K-
dependent signaling (i.e. Pten, Egfr, and PIK3CA, among others [ref.
23]) may transform these cells in part by cooperating with
oncogenic K-ras. The potential importance of secondary somatic
mutations in promoting oncogenic K-ras-induced lung tumorigen-
esis is illustrated by the long latencies of adenocarcinomas that
arise in mice engineered to express mutant K-ras, which develop
lung lesions rapidly and with high penetrance, but only a fraction
of the lesions progress into adenocarcinomas and require several
months to do so [3–7].
Findings reported here differed from those reported previously
in a different strain of mice that undergo conditional Pten deletion
Figure 2. Kras
LA1 mice have an accumulation of BASCs at terminal bronchi. Immunofluorescent staining to detect cells at terminal bronchi
that co-express CCSP and SPC. Encircled BASCs in top panels (x10 magnification) illustrated in lower panels at higher magnification (x40). Bar graph
indicates percentages of terminal bronchi with the indicated numbers of BASCs. Calibration bars in images of H&E stained tissues represent 50 mm.
doi:10.1371/journal.pone.0002220.g002
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inactivation was sufficient to increase BASC numbers and induce
lung tumors, which stands in contrast to findings presented here
and elsewhere [18] that Pten deficiency is not sufficient to increase
BASC numbers or induce lung tumors. That previous report also
differed with respect to the genetic events that cooperated with Pten
deficiency. In that study, Pten inactivation accelerated lung
tumorigenesis induced by urethane, a carcinogen that frequently
induces K-ras mutations, but only 2 of 6 tumors evaluated had K-
ras mutations, which leaves open the possibility that urethane
cooperates with Pten loss by inducing somatic mutations of genes
other than K-ras. This stands in contrast to our model in which the
conditional K-ras and Pten alleles recombined in the same (CCSP-
expressing) cells. Hence, the disparate outcomes of these studies
might be related to secondary genetic events in the urethane-
treated mice or differences in experimental design, such as the
genetic backgrounds of the mice or the specific promoter elements
driving Cre expression.
Methods
Reagents
Antibodies purchased for these studies include rabbit anti-
p110a (sc-7174), p110b (sc-7175), SPC (sc-13979), goat anti-CC10
(sc-9772) and PTEN (sc-6818) (Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit anti-total AKT (9272), Ser473-phosphorylated
AKT (9271), Ser21/9-phosphorylated GSK3a/b (9331), total
GSK3 (9332), cleaved caspase-3 (9661), Poly (ADP-ribose)
polymerase (9542), phosphorylated-histone H3 (9701), Ser28-
phosphorylated histone H3 (9713P) (Cell Signaling Technologies,
Danvers, MA), rabbit anti-SPC (WRAB-SPC, Seven Hills
Bioreagents, Cincinnati, OH), rabbit anti-CCSP (07-623, Upstate
Biotechnologies, Lake Placid, NY), FITC-conjugated anti-Sca-1
(557405), biotin-conjugated anti-CD45 (553771) biotin-conjugat-
ed-CD31 (558737), PE-conjugated anti-CD34 (12-0341-33,
eBioscience), anti-rabbit IgG Alexa Flour 488 (A11008), and
anti-goat IgG Alexa Flour 594 (A11058) (Invitrogen, Carlsbad,
CA). Other purchased reagents include streptavidin-APC (554067,
BD Pharmigen), TSA kits 22 (T20932), 25 (T20935), and
27(T20937), Avidin/Biotin blocking kit (00-4303) (Invitrogen),
Dispase (354235, BD Biosciences), collagenase/dispase
(10269638001, Roche Biosciences), and 7-aminoactinomycin D
(A1310, Invitrogen).
Mouse studies
To test whether PI3K promotes tumor development, 9 K-
ras
LA1 mice were treated for 4 weeks with 2 mg/kg/d intra-gastric
PX-866, a small molecule inhibitor of PI3K [12], and 12 were
given vehicle beginning at 4 months, an age at which lung lesions
(AAH and adenomas) are measurable by micro-computed
tomography scans. Mice were subjected to these scans at the
beginning and completion of treatment to count lesion numbers
and evaluate changes in lesion volumes over time as previously
reported [24].
Prior to their initiation, all mouse studies were submitted to and
approved by the Institutional Animal Care and Use Committee at
the University of Texas–M. D. Anderson Cancer Center. Mice
received standards of care and were euthanized according to the
standards set forth by the IACUC. Mice and cells and were
obtained through collaborations with Dr. Tyler Jacks, MIT
(Kras
LA1 mice, and Kras
LSL mice), Dr. Hong Wu, UCLA (Pten
flox
mice), and Dr. Francesco Demayo, Baylor College of Medicine
(CCSP
Cre mice).
Figure 3. BASCs express p110a and have Ser473-phosphorylated AKT. Immunofluorescent staining of tissue sections to detect triply
stained (CCSP/SPC/p110a or pAKT) cells at terminal bronchi. BASCs encircled (x40 magnification). Calibration bar in lower right panel represents
50 mm.
doi:10.1371/journal.pone.0002220.g003
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We performed immunohistochemical analysis of PI3K on a
tissue microarray containing AAH (n=17), solid adenomas
(n=31), mixed solid/papillary adenomas (n=36), papillary
adenomas (n=45), and adenocarcinomas (n=14) to determine
whether the levels of PI3K changed during malignant progression.
We analyzed the expression of PI3K isoforms (p110a and b).
For immunohistochemical staining, 4 mm paraffin-embedded
sections were baked at 60uC for 30 min and then cooled to
ambient temperature. Sections were sequentially incubated in
Xylene (5 min twice), 100% ethyl alcohol (5 min twice), 95% ethyl
alcohol (5 min twice), and 80% ethyl alcohol (5 min). After
washing with water, the sections were antigen-retrieved using
citrate buffer (pH 6.0, DAKO) in a steamer for 20 min and cooled
to ambient temperature. Sections were then washed with TBS-T
and quenched with 3% hydrogen peroxide in TBS for 10 min,
blocked for Avidin/Biotin activity, and incubated with primary
antibody as follows: For p110a and p110b staining, sections were
blocked with 5% goat serum for 1 h, incubated with primary
antibodies for 1 h at ambient temperature, and then washed with
TBS-T; for Ser28-phosphorylated histone H3 staining, sections
were blocked with 10% goat serum at 4uC overnight, incubated
with primary antibody for 30 min at ambient temperature, and
washed with TBS-T. The staining was developed using DAB
substrate system. Negative controls included omission of the
primary antibody and pre-incubation of primary antibody with
blocking peptide. Staining was quantified by one investigator
(M.G.R.) blinded as to treatment group. Intra-lesional expression
was scored based on staining intensity and extension as described
previously [24].
Detection of BASCs in lung tissues
Antigens were retrieved from mouse lung tissues with 0.01 mol/
L citrate buffer (pH 6; DakoCytomation, Glostrup, Denmark) for
25 min in a steamer. The slides were quenched in 1.5% hydrogen
peroxide in Tris-buffered saline for 10 minutes and blocked in
DAKO serum-free protein block (Dako) for 1 h at ambient
temperature. The slides were then incubated with anti-SPC (sc-
7705, Santa Cruz Biotechnology; WRAB-SPC, Seven Hills
Bioreagents) and anti-CCSP (07-623, Upstate Biochemicals)
antibodies at 4uC overnight. The immunofluorescence was
developed using TSA kits 25 and 22 (Invitrogen) on the basis of
the manufacturer’s instructions. We used blocking peptides and
omitted the primary antibodies as negative controls to determine
the specificity of the immunostaining results. Immunofluorescence
was visualized using a microscope with a reflected fluorescence
system (Olympus Model IX71SIF-2). Color acquisition and
background fluorescence were optimized by using the DPCon-
troller and DPManager software (Olympus).
BASC isolation and culture
The mice were killed after 12 weeks, and the lungs were
perfused with 10 mL of Hank’s balanced salt solution through the
right ventricle until they were cleared of blood. The tracheas were
injected with Dispase (undiluted liquid, BD Biosciences) followed
by 0.5–1 mL 1% LMP agarose in water. The lungs were placed on
Figure 4. PX-866 treatment decreases BASC numbers in Kras
LA1 mice. Immunofluorescent staining to detect cells at terminal bronchi that
co-express CCSP and SPC. Encircled BASCs in top panels (610 magnification) illustrated in lower panels at higher magnification (640). Bar graph
indicates percentages of terminal bronchi with the indicated numbers of BASCS. Calibration bars in images of H&E stained tissues represent 50 mm.
doi:10.1371/journal.pone.0002220.g004
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D-4527) and 2 mg/mL of collagenase/dispase (100 mg/mL,
Roche) in phosphate-buffered saline at 37u C for 45 min, filtered
(100 mm followed by 40 mm pore-sized filter), and centrifuged.
The resulting pellets were resuspended in 2 mL of PF10 (10% fetal
bovine serum in phosphate-buffered saline), which typically yields
1–2 million total cells per mouse. The red cells were lysed. BASCs
were isolated by sorting of the Sca-1
pos CD45
neg Pecam
neg
CD34
pos cell population on a three-laser 13-color FACS Aria
fluorescence-activated cell sorter (BD Biosciences) that is capable
of sorting four sub-populations at a low pressure with a maximum
rate of 20 million cells/hour. BASCs represented approximately
0.1% of the total sorted cell population.
The uniformity or purity of the sorted cells was not routinely
checked because the cells of interest would have been consumed in
the process. That being said, the cells were sort-purified to the
highest possible purity by gating on size (by forward and side
scatter), excluding doublets (by forward scatter width versus area
and side scatter width versus area), and isolating cells with
the markers of interest. In addition, the uniformity of the sorted
cell populations used in these assays was reflected by the
reproducibility of our findings; the differentiation and colony
formation assays were performed each time using cells derived
from three different mice, which yielded similar results.
For colony formation assays, the sorted cells were plated in
DMEM/HEPES/10% FBS/Pen-Strep/L-glutamine on 96-well
plates with feeder cells (irradiated DR4 mouse embryo fibroblasts,
SCRC-1045.1, American Type Culture Collection, Manassas,
VA) to maintain the undifferentiated state (1000 cells per well).
PX-866 was added to the cultures the day following plating. For
differentiation assays, BASCs were plated for 7 d on 96-well plates
(10,000 cells per well) coated with 100 mL growth factor-reduced
Matrigel (356231, BD Biosciences) and subjected to immunoflu-
orescent staining for SPC and CCSP as described [8]. The yield of
BASCs (Sca-1
pos CD45
neg Pecam
neg CD34
pos) is typically 0.1% of
sorted cells from the lung.
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Figure 5. PX-866 inhibits BASC expansion in vitro. (A) Sorted cells co-express SPC and CCSP. Kras
LA1 whole lung tissues were dissociated and
sorted to isolate Sca-1
pos CD45
neg CD31
neg CD34
pos cells (P4 and P5 in left and middle panels, respectively), which were subjected to
immunofluorescent staining (x40 magnification, right panel). Calibration bar in far right panel represents 10 mm. (B) BASCs form colonies when
plated on feeder cultures. Photograph of colony (x10 magnification) formed upon initial plating (P1) and passage 2 (P2). Calibration bar in panel on
right represents 50 mm. (C) BASCs differentiate when plated in matrigel. Cells were stained after 7 d in matrigel (x10 magnification) and the numbers
of cells with features of alveolar type II cells (CCSP
neg SPC
pos), clara cells (CCSP
pos SPC
neg), or BASCs (CCSP
pos SPC
pos) were counted and expressed as
the percentages of the total 158 counted cells in a pie chart. Examples of cells with features of ATII cells (ATII) and clara cells (CC) are indicated.
Calibration bar in far right panel represents 50 mm. (D) PX-866 inhibits BASC colony formation. Photographs (x10 magnification) and quantification of
colonies per well (5 wells per condition) formed after 6 d in the presence or absence of PX-866. Calibration bar in panel on right represents 50 mm.
doi:10.1371/journal.pone.0002220.g005
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PLoS ONE | www.plosone.org 7 May 2008 | Volume 3 | Issue 5 | e2220Figure 6. Loss of PTEN expression in BASCs from Pten
D5/D5; Kras
Lox/+; CCSP
Cre/+ mice. Immunofluorescent staining of tissue sections to
detect triply stained (CCSP/SPC/PTEN) cells at terminal bronchi. BASCs (encircled) illustrated at610 magnification. Calibration bar in lower right panel
represents 100 mm.
doi:10.1371/journal.pone.0002220.g006
Figure 7. BASC expansion at terminal bronchi of Pten
D5/D5; Kras
Lox/+; CCSP
Cre/+ mice. Immunofluorescent staining to detect cells at
terminal bronchi that co-express CCSP and SPC. BASCs (encircled) illustrated at 640 magnification. Bar graph indicates percentages of terminal
bronchi with the indicated numbers of BASCS. Calibration bar in lower right panel represents 100 mm.
doi:10.1371/journal.pone.0002220.g007
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